ABVD is a four-drug chemotherapy regimen used primarily to treat Hodgkin lymphoma. The acronym stands for the first letters of each drug: Adriamycin (doxorubicin), bleomycin, vinblastine, and dacarbazine. It has been a standard treatment for decades, with long-term survival rates above 95% for early-stage disease.
The Four Drugs and How They Work
Each drug in the ABVD combination attacks cancer cells through a different mechanism, which is why they’re bundled together. Doxorubicin (the “A,” branded as Adriamycin) works by wedging itself between the strands of a cancer cell’s DNA, blocking the cell from copying itself. It also generates a burst of unstable oxygen molecules inside the cell that damage its internal structures beyond repair. Vinblastine disrupts the tiny scaffolding that cells use to pull themselves apart during division, freezing the process mid-split. Bleomycin directly fragments DNA strands. Dacarbazine damages DNA by attaching chemical groups to it, preventing it from being read or replicated.
Because each drug targets a different vulnerability, cancer cells have a much harder time developing resistance to the combination than they would to any single agent.
Treatment Schedule and Duration
A single ABVD cycle lasts 28 days. You receive all four drugs intravenously on day 1 and again on day 15, then have the remaining days to recover before the next cycle begins. The entire infusion appointment typically takes a few hours.
How many cycles you need depends on the stage of your disease. For early-stage Hodgkin lymphoma, a typical course is 2 to 4 cycles followed by radiation therapy, or about 6 cycles if radiation isn’t used. For advanced-stage disease, the standard is 6 cycles, sometimes followed by radiation to areas of remaining concern. Your oncologist may adjust this based on interim PET scans that show how quickly the cancer is responding.
Success Rates
ABVD is one of the more effective chemotherapy regimens in oncology. For early-stage Hodgkin lymphoma, long-term progression-free survival rates range from 85% to 95%. A prospective study following patients for a median of about six and a half years found overall survival of 96% and progression-free survival of 84%. Patients with stage IA or IIA disease without large masses in the chest did even better: 97% overall survival and 88% progression-free survival.
For advanced-stage disease, progression-free survival rates with modern PET-adapted approaches range from 75% to 90%. These numbers have improved over time as doctors have gotten better at tailoring treatment intensity to each patient’s early response.
Common Side Effects
The most predictable short-term side effects include nausea, fatigue, and hair loss. Nausea can often be well controlled with anti-nausea medications given before and after each infusion. Hair loss typically begins within about three weeks of the first treatment and is usually temporary, with regrowth starting after treatment ends.
Low blood counts are a near-universal effect. Your white blood cells, red blood cells, and platelets all drop as the drugs affect fast-dividing cells in your bone marrow. This means a higher risk of infections (from low white cells), persistent tiredness and shortness of breath (from low red cells), and easier bruising or bleeding (from low platelets). Blood work is checked regularly between infusions to monitor these levels.
Dacarbazine can cause a burning sensation or pain at the infusion site as it enters the vein. If the drug leaks outside the vein into surrounding tissue, it can cause significant irritation and even scarring. Nurses typically monitor the IV site closely during this part of the infusion. Let your care team know immediately if you feel burning or stinging.
Lung and Heart Risks
Two of the four drugs carry specific organ risks that require monitoring throughout treatment.
Bleomycin can injure lung tissue, a condition that shows up as a dry cough, shortness of breath, or chest discomfort. There are no universally agreed-upon diagnostic criteria for bleomycin lung toxicity, which makes monitoring tricky. Many centers check lung function before and during treatment using a breathing test that measures how well your lungs transfer oxygen into your blood. If that measure drops significantly, your oncologist may remove bleomycin from the remaining cycles while continuing the other three drugs. The threshold for stopping varies between institutions, ranging from a 15% to a 40% decline in lung function, reflecting the lack of consensus.
Doxorubicin can damage the heart muscle over time, and the risk increases with cumulative exposure. The recommended lifetime maximum dose is 400 to 450 mg per square meter of body surface area. For a standard ABVD course of 6 cycles, the total doxorubicin dose stays well below this ceiling. Heart function is typically monitored with an echocardiogram or a nuclear scan at baseline and periodically during treatment. The risk of heart damage from ABVD alone is low, but it becomes relevant if you ever need additional doxorubicin-based treatment later in life.
Fertility Effects
For young men, ABVD causes a significant but generally temporary drop in sperm count. A review of data from over 1,300 patients found marked deterioration in sperm count at 6 months after treatment, with greater reductions seen in those who received more cycles. The key distinction is that ABVD’s effects on male fertility tend to be reversible, unlike some alternative regimens (such as BEACOPP) whose effects are more often permanent. Recovery timelines vary, but many men see sperm counts return to baseline within 1 to 2 years.
For women, the fertility impact depends heavily on age and the number of cycles received. Younger women generally have a better chance of preserving or regaining normal ovarian function after treatment. Regardless of sex, if you’re of reproductive age and planning to start ABVD, it’s worth discussing fertility preservation options like sperm banking or egg freezing before your first cycle, since these options become less viable once treatment is underway.
What the Treatment Day Feels Like
On infusion days, you’ll typically arrive at a cancer center’s outpatient chemotherapy unit. Anti-nausea medications are given first through an IV line, followed by each of the four drugs in sequence. The entire visit, including pre-medications and observation afterward, usually takes several hours. Most people feel relatively well during the infusion itself, with nausea and fatigue building over the following 24 to 72 hours. The second week of each cycle, before your day-15 infusion, is often when you feel your best.
Doxorubicin is bright red, which can temporarily turn your urine a reddish-orange color. This is harmless but can be startling if you’re not expecting it.